Compare Mongodb Inc (MDB) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mongodb Inc vs Sanofi SA — how do they compare? Mongodb Inc trades at $307.85 (market cap $26.01B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is far larger — about 4× Mongodb Inc's market cap, and Sanofi SA pays a 5.5% dividend while Mongodb Inc pays none. Which is the better fit depends on your goals.
| MDB | SNY | |
|---|---|---|
Market Cap | $26.01B | $104.83B |
Sector | Technology | Health |
52-Week High | $440.25 | $52.34 |
52-Week Low | $201.08 | $41.33 |
Enterprise Value | $23.61B | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MDB trades at $307.65, down 1.5% today, with a bearish technical signal despite recent earnings beats. Revenue growth is strong at $2.01B for 2025, but the company remains unprofitable with a net margin of -1.12%. Analyst sentiment is overwhelmingly positive with an 81.81% buy rating and a $400.39 consensus price target, though negative cash flow and high valuation multiples present challenges.
The outlook hinges on MDB's ability to sustain revenue momentum and achieve profitability. Investment opportunity lies in its leadership in database solutions and AI-driven demand growth. Key risks include persistent cash burn, competitive pressures, and high valuation metrics that may not justify current losses if growth slows.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
